Caresyntax, a vendor-neutral precision surgery platform, announced it raised a total commitment of $180 million through a series C extension and growth debt expansion round. The investors in the $180 million round include Symbiotic Capital, MTIP AG, BIONIQ Capital, PFM Health Sciences, Pictet Alternative Advisors, surgical.ai, BlackRock Innovation Capital, Aescuvest, Optum Ventures, Cure Capital, Relyens Group, Vesalius Biocapital, Lauxera Capital, Plug & Play Growth Fund, and ProAssurance.
This financing features $80 million of equity and up to $100 million growth debt facility. And Caresyntax is transforming surgery by implementing a scalable end-to-end software and AI platform.
This medical-grade and interoperable platform enables the capture and use of novel data and applications to enhance surgical precision and patient safety. Caresyntax serves 30,000+ surgical professionals across 3,000+ operating rooms worldwide, delivering automation and actionable insights to hospitals, medical device companies, and insurance groups.
Caresyntax’s platform also addresses critical data shortfall and fragmentation challenges that hinder the progress of the precision and data-assisted surgery market. And Caresyntax utilizes tech and AI to collect, integrate, and analyze unique and comprehensive data, offering caregivers real-time and long-term clinical decision support that enhances the patient journey, boosts hospital operational efficiency, and drives better patient outcomes and profitability.
Through operations that span the US and EMEA the company is experiencing record demand for its solutions from both private and public hospitals. And its proven record of reducing costs, increasing profitability and improving patient outcomes has created a unique set of differentiators.
This funding follows Caresyntax’s successful first half of the year, marked by over 75% revenue growth and increased margins. It also highlights the expanding recognition and adoption of Caresyntax’s innovative platform in US and EMEA healthcare systems.
The funding is being used to scale customer adoption of surgical software tools and to continue developing the company’s AI and edge-to-cloud applications. The funding round also enables the Caresyntax M&A strategy, with the company acquiring several US surgical data and technology assets last year and looking to complete several acquisitions this year and in the future.
KEY QUOTES:
“Symbiotic is thrilled to support Caresyntax in its mission to enhance surgical outcomes through its innovative platform, delivering benefits to stakeholders throughout the healthcare ecosystem. We were impressed with Caresyntax’s growth across hospitals, medtechs and insurers and look forward to working together to continue to scale their platform.”
- Himani Bhalla, Chief Investment Officer of Symbiotic Capital
“MTIP proudly backs the forefront of surgical intelligence through our investment in Caresyntax. What drew us to Caresyntax was not only their stronghold in a rapidly expanding sector but also their unique platform approach, seamlessly integrating workflow software and data-driven solutions. This investment reflects our commitment to supporting innovative solutions that enhance patient care and empower healthcare professionals globally. Together, we’re driving the future of smarter and safer surgeries, making a meaningful impact on the world.”
- Katrin Vatiska, Investment Partner at MTIP
“Together with our partners and investors, we are working towards deploying precision surgical tools, empowered by data and AI, to improve patient outcomes. This financing is not just an investment in Caresyntax, but an investment in the future of surgery. My gratitude extends to our investors who contribute to and believe in the power of smart data and AI usage in the operating room.”
- Dennis Kogan, Co-Founder and CEO of Caresyntax
“Caresyntax is uniquely positioned to revolutionize the operating room—presently a black box—by transforming it into a data lake. This transformation is aimed at enhancing surgical procedures to make them smarter, safer, and more broadly accessible.”
- Patrick Pfeffer, CEO of Aescuvest
“We are grateful for this significant investment in Caresyntax, which strengthens our balance sheet at an important inflection point for the adoption of digital surgery, AI and automation tools. The capital enables Caresyntax to deliver increased growth momentum, platform adoption and customer ROI; it also catalyzes M&A and corporate development opportunities.”
- Bjoern von Siemens, CFO and CBO of Caresyntax
